Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

HERNEXEOS product image Product image This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) ...

The accelerated approval for patients with HER2 (ERBB2)-mutated disease follows an approval last August for use after prior ...

Synthekine has entered a clinical trial partnership and supply agreement with Merck (MSD) to investigate STK-012 in combination with Keytruda (pembrolizumab) and chemotherapy in patients with ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. This episode, titled Dual Immunotherapy Strategies in Metastatic ...

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

(Trinity Capital) with $50 million drawn down at closing, and access of up to an additional $80 million Cash and cash equivalents of $119.7 million, as of December 31, 2025, together with $93.5 ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC). 1 This indication ...

Please provide your email address to receive an email when new articles are posted on . Gaps in access remain, though, as almost half of patients did not receive next-generation sequencing. “These ...